Materias dentro de su búsqueda.
Mostrando 1,881 - 1,900 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.29s Limitar resultados
  1. 1881
    “…HIF-2α expression is frequently higher in HER2-overexpressing tumours and is associated with worse disease-specific survival in HER2-positive breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
  2. 1882
    “…It has been reported that HER receptors are overexpressed in breast cancer including TNBC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
  3. 1883
    “…About 75% of ovarian cancer patients relapse and/or develop chemo‐resistant disease after initial response to standard‐of‐care treatment with platinum‐based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
  4. 1884
    por Xu, Chaoyang, Jin, Shuxun, Huang, Liming
    Publicado 2019
    “…Positive expression of Lin28 was associated with lymph node metastases (P<0.001), HER-2 (P=0.024), estrogen receptor (P=0.039), and progesterone receptor (P=0.027). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of Lin28 is correlated with prognosis and expression of HER-2 and steroid receptors in breast cancer
  5. 1885
    Publicado 2019
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
  6. 1886
    Publicado 2017
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis: Erratum
  7. 1887
    por Wang, Gang, Wu, Chun, Wang, Yi, Dai, Jiangtao
    Publicado 2019
    “…Computed tomography revealed a giant mixed-density space-occupying lesion in the left side of her thoracic cavity, originating possibly from the pleura. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A girl with a giant fibrolipoma in her thoracic cavity: a rare case report
  8. 1888
    “…Trastuzumab is integral to HER2+ cancer treatment, but its therapeutic index is narrowed by the development of resistance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
  9. 1889
    “…ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy and biological rationale of chemotherapy plus anti-HER2 therapy and ZOL as a part of neoadjuvant therapy has not been previously tested. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
  10. 1890
    “…In addition, the crosstalk between radiation-induced activities and EGFR-, and HER2-related downstream pathways may contribute to the enhancement of radiosensitivity. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
  11. 1891
    “…HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target
  12. 1892
    por Roberts, Leah May, Carnivale, Bruce
    Publicado 2019
    “…Here, we report the case of a 20-year-old female that presented to her internal medicine physician after suffering from secondary amenorrhea. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Perrault Syndrome Diagnosis in a Patient Presenting to Her Primary Care Provider with Secondary Amenorrhea
  13. 1893
    por Berwart, Julia, Peccatori, Fedro A
    Publicado 2019
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment
  14. 1894
    “…When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer
  15. 1895
    “…Patients were divided into HER2-negative and HER2-positive groups and chi-square test was used to compare the demographics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effects of HER2 status on the prognosis of male breast cancer: a population-based study
  16. 1896
    “…We validated these findings using HER2+ BCBM cells compared to parental breast cancer cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
  17. 1897
    “…To facilitate their targeted delivery, the human epidermal growth factor receptor-3 (HER3)-specific aptamer A30 was used. The in vitro results described in this work indicate that combining the highly specific HER3 aptamer with cytotoxic siRNAs targeting (EEF2, PLK1, GRK4 and SKIP5) can inhibit its activity and ultimately suppress proliferation of HER3 positive breast cancer cells.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras
  18. 1898
    “…BACKGROUND: The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
  19. 1899
    “…CONCLUSION: We observed that HER2/neu is expressed in one-third of high-grade ECs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation
  20. 1900
    “…No relationship was found between HER2 amplification and KRAS status (p = 0.052). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients
Herramientas de búsqueda: RSS